Top

Published in:

01-02-2012 | Short Commentary

Does fingolimod in multiple sclerosis patients cause macular edema?

Authors: Kiran Turaka, Joseph Shepard Bryan

Published in: Journal of Neurology | Issue 2/2012

Abstract

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system and is the common cause of optic neuritis. Fingolimod, an immunosuppressive agent, is used in MS to prevent acute exacerbations. We report a case of relapsing–remitting MS treated with fingolimod. The patient presented with an acute decrease in vision in the left eye. Eye examination showed clinical macular edema (ME) in the left eye, which was confirmed on fluorescein angiogram and optical coherence tomography (OCT). After discontinuation of fingolimod and treatment with topical corticosteroid medication, there was complete resolution of the ME. The ME as a side-effect of fingolimod is reversible after discontinuing, which was seen on OCT.

Derwenskus J (2011) Current disease—modifying treatment of multiple sclerosis. Mt Sinai J Med 78:161–175PubMedCrossRef

Huggins A, Sergott RC (2011) Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting–relapsing multiple sclerosis: with special emphasis upon visual safety. Curr Opin Ophthalmol Sep 22. [Epub ahead of print]

Comi G, O’Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L, FTY720D2201 Study Group (2010) Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 16:197–207PubMedCrossRef

[No authors listed] (2009) Trial watch: Phase III promise for oral multiple sclerosis therapy Nat Rev Drug Discov 8:98

Chun J, Brinkmann V (2011) A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 12:213–228PubMed

Yeh EA, Weinstock-Guttman B (2011) Fingolimod: an oral disease—modifying therapy for relapsing multiple sclerosis. Adv Ther 28:270–278PubMedCrossRef

Saab G, Almony A, Blinder KJ, Schuessler R, Brennan DC (2008) Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient. Arch Ophthalmol 126:140–141PubMedCrossRef

Chun J, Hartung HP (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33:91–101PubMedCrossRef

Kappos L, Radue EW, O’Connor P, for the FREEDOMS Study Group (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401PubMedCrossRef

Title: Does fingolimod in multiple sclerosis patients cause macular edema?
Authors: Kiran Turaka
Joseph Shepard Bryan
Publication date: 01-02-2012
Publisher: Springer-Verlag
Published in: Journal of Neurology / Issue 2/2012
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-011-6367-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Does fingolimod in multiple sclerosis patients cause macular edema?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Central pontine myelinolysis associated with pancreatic diabetes

Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design

Oral anticoagulant-associated intracerebral hemorrhage

Mitochondrial DNA polymorphisms/haplogroups in hereditary spastic paraplegia

Communications of the European Neurological Society

Erratum to: Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume